Received Jan 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 2 | 945659 | IM / LA |
HEADACHE, MIGRAINES, BODY AND JOINT ACHES, FELT FEVERISH, REDNESS AND ITCHING AROUND INJECTION SITE., DIZZINESS AND LIGHTHEADED. TREATMENT WAS SUMATRIPTAN FOR THE HEADACHE, BENADRYL, MORPHONE, EPINEPHRENE, SODIUM CHLORIDE, MAGNESIUM, AND PREDNISONE. PATIENT IS FEELING BETTER WITH A SLIGHT HEADACHE.
LARYNGITIS (2 WEEKS PRIOR)
ADHD, PTSD, CHRONIC MIGRAINE WITHOUT AURA WITHOUT ATATUS MIGRAINOSUS, CHRONIC INSOMNIA, OBESITY, SCOLIOSIS, INAPPROPRIATE SINUS TACHYCARDIA, BIPOLAR 1 DISORDER, PEPTIC ULCER DISEASE, VERTIGO, GERNERALIZED ANXIETY DISORDER WITH PANIC ATTACKS, HISTORY OF VITAMIN D DEFICIENCY, DE QUERVAIN'S TENOSYNOVITIS, SEASONAL AFFECTIVE DISORDER, WELL WOMAN EXAM WITH ROUTINE GYNECOLOGICAL EXAM, HIDREADENITIS SUPPURATIVA OF MULTIPLE SITES, PVCS, PREDIABETES
METHYLPHENIDATE, OXCARBAZEPINE, HYDROXYZINE, TRAZODONE, FLUTICASONE PROPIONATE, PROPRANOLOL, MULTIVITAMIN, CETIRIZINE, COUGH DROPS
LATEX, TAMAFLU, ASPRIN, NAPROXIN, GABAPENTIN, IBUPROFEN, SOME SLEEP AIDS, LAMOTRAGINE,
CBC, CMP, DIFFERENTIAL MORPHOLOGY REVIEW, INFLUENZA A/B/RCV/COVID PCR AND CT WITHOUT CONTRAST.